KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
Kodiak Sciences (KOD) stock rose 178% to $89.92 after two experimental eye drugs met primary endpoints in a Phase 3 trial. Analysts raised price targets, with Jefferies setting a $112 target. Investor Martin Shkreli criticized the results, citing competition from Regeneron's Eylea. KOD is up 141% in September and 222% year-to-date.
How this was made
The 30-second read
Why it matters
The trial’s success drove a massive intraday rally and prompted analysts to raise price targets, indicating strong market reaction.
Market read
First‑report Phase 3 data for a mid‑cap biotech, generating significant price movement and analyst upgrades.
What to watch
Potential regulatory hurdles and pricing competition could temper long‑term upside.
Background
Kodiak Sciences (KOD) is a Nasdaq‑listed biotech focused on ocular therapies. The Daybreak trial evaluated two candidates, Zenkuda and KSI‑501, in wet age‑related macular degeneration.
Ticker impact
Kodiak Sciences reported Phase 3 Daybreak trial results meeting primary endpoints, triggering a 178% stock surge.
likely continued upside as investors price in successful trial outcomes
Phase 3 data is material for a biotech; the stock already rallied sharply, and analysts raised price targets, indicating further buying pressure.
Market effects
Strengthens the wet AMD therapeutic segment and may pressure competing eye‑drug makers.
U.S. biotech sector gains on the news; limited immediate effect outside the U.S.
Highlights the competitive landscape for anti‑VEGF therapies worldwide.
Counterpoint
Short sellers like Shkreli argue the data may not translate to market share against established Eylea biosimilars.
Key entities
- companyKodiak Sciences
Biotech developer of eye‑drug candidates Zenkuda and KSI‑501.
- companyRegeneron
Maker of Eylea, the established wet AMD treatment.
